BeOne Medicines (NASDAQ:ONC) Announces Earnings Results, Beats Expectations By $0.65 EPS

BeOne Medicines (NASDAQ:ONC) issued its earnings results on Wednesday. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.65, Zacks reports. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.

Here are the key takeaways from BeOne Medicines’ conference call:

• Q2 results exceeded expectations: Revenue reached $1.7 billion, up 30% year over year, while GAAP diluted EPS increased 144% to $2.05. The company raised 2026 revenue guidance by $300 million and GAAP operating-income guidance by $250 million.
• BRUKINSA continued its strong commercial momentum, generating more than $1.2 billion in global revenue, up 31%, with the highest sustained new-patient starts since launch and growth across all five approved indications. Management cited improving adherence, favorable early treatment duration and supportive real-world survival data.
• Pipeline and regulatory progress accelerated. FDA approval of BEQALZI in relapsed/refractory mantle cell lymphoma and positive Phase III MANGROVE results support a potential chemo-free frontline MCL regimen, with global submissions planned for the second half of 2026; several solid-tumor assets are also moving toward pivotal trials.
• The CELESTIMO 301 zanubrutinib/sonrotoclax regimen did not achieve statistical superiority on the uMRD endpoint versus venetoclax/obinutuzumab. The study will continue to its primary progression-free-survival endpoint, but the result introduces uncertainty despite management’s confidence in eventual PFS superiority.
• BeOne plans substantial continued investment in its pipeline, with 2027 operating expenses expected to grow at a rate similar to recent years. The company also announced a $300 million expansion of its Hopewell, New Jersey manufacturing site, while noting potential future biosimilar competition for XGEVA in its Amgen portfolio.

BeOne Medicines Stock Performance

NASDAQ ONC traded up $6.33 during trading hours on Wednesday, hitting $329.35. The company’s stock had a trading volume of 288,902 shares, compared to its average volume of 279,403. The company’s 50 day simple moving average is $293.98 and its two-hundred day simple moving average is $308.75. BeOne Medicines has a 12 month low of $253.95 and a 12 month high of $385.22. The company has a market cap of $36.14 billion, a P/E ratio of 73.68 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27.

Insider Activity at BeOne Medicines

In related news, CEO John Oyler sold 61,397 shares of the business’s stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $317.67, for a total transaction of $19,503,984.99. Following the completion of the sale, the chief executive officer directly owned 9,180 shares in the company, valued at approximately $2,916,210.60. The trade was a 86.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Chan Henry Lee sold 1,044 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $323.69, for a total transaction of $337,932.36. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 344,404 shares of company stock worth $105,264,141. Company insiders own 6.19% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

A number of institutional investors have recently bought and sold shares of the stock. EFG International AG bought a new position in shares of BeOne Medicines during the 4th quarter valued at approximately $25,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines in the 2nd quarter worth $35,000. Group One Trading LLC purchased a new stake in BeOne Medicines in the 4th quarter worth $61,000. EverSource Wealth Advisors LLC bought a new stake in BeOne Medicines during the second quarter valued at about $68,000. Finally, Coldstream Capital Management Inc. purchased a new position in shares of BeOne Medicines in the third quarter valued at about $201,000. 48.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on ONC shares. Truist Financial lifted their target price on shares of BeOne Medicines from $413.00 to $416.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Zacks Research lowered BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 3rd. Morgan Stanley reiterated an “overweight” rating and issued a $395.00 price objective on shares of BeOne Medicines in a report on Thursday, May 7th. Nomura upgraded shares of BeOne Medicines to a “strong-buy” rating in a report on Monday, July 27th. Finally, Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BeOne Medicines presently has an average rating of “Moderate Buy” and a consensus target price of $394.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.